Lezack Adam 4

What Happened
Adam Lezack, a director of Beta Bionics (BBNX), disposed of a total of 1,998 shares in two open-market sales and received a grant of 16,965 restricted stock units (RSUs). On 2026-05-21 he sold 1,000 shares at $9.95 ($9,950) and was granted 16,965 RSUs at $0.00 (award value shown as $0); on 2026-05-22 he sold 998 shares at $11.21 ($11,188). Total proceeds from the sales were approximately $21,138. The RSU grant is an award (not a cash purchase) and does not represent an immediate cash outlay or realized gain.

Key Details

• Transaction dates and prices:
  • 2026-05-21: Sale of 1,000 shares at $9.95 — $9,950 (Footnote: sold pursuant to a Rule 10b5-1 plan adopted 7/31/2025).
  • 2026-05-21: Award of 16,965 RSUs at $0.00 under the Issuer’s 2025 Equity Incentive Plan.
  • 2026-05-22: Sale of 998 shares at $11.21 — $11,188.
• Shares owned after transaction: Not disclosed in the information provided in this filing.
• Notable footnotes: F1 = sales executed under a pre-established Rule 10b5-1 plan (adopted July 31, 2025); F2 = RSU award under the 2025 Equity Incentive Plan.
• Filing timeliness: The Form 4 was filed on 2026-05-26 for transactions occurring 2026-05-21 and 2026-05-22; this filing appears late (may be marked L for late), which can affect disclosure timeliness but does not change the facts of the transactions.

Context

• The RSU grant is an award (A) — typically subject to vesting and not an immediate market purchase; the filing does not show vesting terms.
• The sales were executed under a Rule 10b5-1 plan, which is a prearranged trading plan that insiders use to sell shares at scheduled times; such sales are often routine and may not indicate a change in the insider’s view of the company.
• For retail investors, purchases or open-market buys generally signal a stronger affirmative view; here the activity is primarily an award grant plus routine, preplanned sales.